Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study

In the prospective PRECISION study of 118 eligible patients with resectable colorectal oligometastases, pretreatment Guardant360 genomic profiling and postoperative Guardant Reveal MRD were each independently associated with shorter recurrence-free survival (multivariable HRs 3.28 and 4.07); patients with both a poor genomic profile and postoperative MRD had the highest recurrence risk (RFS HR 13.28), and those with an optimal profile and undetected MRD had a 2-year RFS of 77.8%.

ESMO Open